|____Semperform____|___________________|___________________|___________________|
|____Umsatzerlöse__|_______________19,8|______________-0,3%|_______________19,9|
|____EBITDA________|________________3,1|_____________-11,9%|________________3,5|
|____EBIT__________|________________2,1|_____________-16,3%|________________2,6|
|____Semperseal____|___________________|___________________|___________________|
|____Umsatzerlöse__|_______________28,7|______________13,1%|_______________25,4|
|____EBITDA________|________________4,2|______________29,5%|________________3,3|
|____EBIT__________|________________2,6|______________50,8%|________________1,8|
|Sektor Medizin | | | |
|(Sempermed)_______|___________________|___________________|___________________|
|Umsatzerlöse______|______________192,9|______________>100%|_______________77,5|
|EBITDA____________|______________105,3|______________>100%|________________4,8|
|EBIT______________|______________100,2|______________>100%|________________4,3|
Rückfragehinweis:
Monika Riedel
Director Group Brand Management, Corporate Spokesperson
+43 676 8715 8620
monika.riedel@semperitgroup.com
Judit Helenyi
Director Investor Relations
+43 676 8715 8310
judit.helenyi@semperitgroup.com
www.semperitgroup.com
Ende der Mitteilung euro adhoc
=-------------------------------------------------------------------------------
Anhänge zur Meldung:
=---------------------------------------------
http://resources.euroadhoc.com/documents/15/5/10725755/0/2021-05-19_Semperit_Presseinformation_Q1_2021.pdf
(END) Dow Jones Newswires
May 19, 2021 01:39 ET (05:39 GMT)